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Abstract 
Purpose: To describe two patients with Behçet’s disease who underwent cataract surgery 
one week after infliximab administration.  
Methods: Patients received preoperative antibiotic therapy with 0.5% levofloxacin eye 
drops and 500 mg levofloxacin oral tablets, followed by cataract surgery one week after 
infliximab administration. We observed ocular findings following cataract surgery, 
phacoemulsification-aspiration, and posterior chamber intraocular lens implantation.  
Results: There were no intraoperative complications. Neither ocular inflammatory attacks 
nor infectious complications were found in the operated eyes of both patients during 
follow-up.  
Conclusion: Administration of infliximab one week before cataract surgery is safe and 
effective for patients with Behçet’s disease. 
 
Introduction 
Infliximab, a humanized antibody against tumor necrosis factor-α (TNF-α), reduces 
uveitis attacks in patients with Behçet’s disease (BD) [1, 2]. Anti-TNF-α therapy increases 
the risk of infections due to the systemic blockade of TNF-α [3]. BD patients often require 
intraocular surgery for the treatment of accompanying cataract, glaucoma, or other 
vitreoretinal problems. However, it is uncertain whether administration of infliximab 
suppresses surgically induced ocular inflammation or increases the rate of surgery-
associated infections in BD patients. Furthermore, the most appropriate timing of 
intraocular surgery after infliximab treatment is unknown. Here, we report two patients 
with BD who successfully underwent cataract surgery one week after the last preoperative 
infliximab administration without suffering any postoperative complications. Case Rep Ophthalmol 2011;2:176–178 
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Case Reports 
Infliximab therapy at 5 mg/kg was intravenously administered at 0 and 6 weeks, and every 8 weeks 
thereafter. Both patients underwent cataract surgery one week after the final preoperative infliximab 
administration. Patients received the following preoperative antibiotic therapy: 0.5% levofloxacin eye 
drops (Santen Pharmaceutical Company, Osaka, Japan) and 500 mg levofloxacin oral tablets (Daiichi 
Pharmaceutical Company, Tokyo, Japan) [4]. Levofloxacin eye drops were administered beginning one 
week before surgery and were administered four times per day for a month. One levofloxacin tablet per 
day was administered in the morning starting the day before surgery and continuing for one week. As 
standard postoperative treatment, 0.1% betamethasone sodium phosphate eye drops (Shionogi and Co., 
Ltd., Osaka, Japan) were administered after surgery four times per day for three months. There were no 
intraoperative complications. 
Case 1 
The patient was a 41-year-old man with a 16-year history of BD. He had a nuclear and cortical 
cataract in the left eye, and underwent phacoemulsification-aspiration and posterior chamber 
intraocular lens (PEA+IOL) implantation with microincision (2.4 mm) of the scleral-corneal tunnel in 
August 2010. His best-corrected visual acuity (BCVA) improved from 0.03 to 0.05. The impaired 
postsurgical visual acuity was due to severe optic nerve atrophy.  
Case 2 
The patient was a 37-year-old man with a one-year history of BD. He had a nuclear and cortical 
cataract in the right eye and underwent PEA+IOL implantation with microincision (2.4 mm) of the 
scleral-corneal tunnel in July 2010. His BCVA improved from counting fingers to 1.2. 
Neither ocular inflammatory attacks nor infectious complications were found in the operated eyes of 
either patient during postoperative follow-up. 
Discussion 
Results from this small case series demonstrate that cataract surgery one week after 
administration of infliximab is safe and effective for patients with BD. No adverse effects, 
such as infection, occurred. 
To our knowledge, there are only two published reports describing cataract surgery 
under infliximab therapy in patients with BD [5, 6]. In these cases, all patients underwent 
surgery about half way through an eight-week interval between doses of infliximab, and 
no patient showed postoperative uveitis or infection. As the serum levels of infliximab 
significantly correlate with its effectiveness in preventing recurrent episodes of uveitis [7], 
this midpoint between infliximab doses may be appropriate in determining timing of 
surgery based on the risk of infection associated with drug concentration. However, the 
trend of serum levels after infliximab administration showed strong interindividual 
variability associated with patient-specific pharmacokinetics, in particular the formation 
of anti-infliximab antibodies [8]. Here we performed cataract surgery one week after the 
last infliximab administration, an anticipated timing of reduced influence by individual 
pharmacokinetics, without suffering any postoperative complications including infection. 
In this shorter period after infliximab administration, serum concentration of infliximab 
is expected to remain high, and thus we believe it to be safer than surgery performed four 
weeks after infliximab administration in terms of preventing surgery-associated 
intraocular inflammation in BD patients. Case Rep Ophthalmol 2011;2:176–178 
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The risk of ocular infection in patients with BD on anti-TNF-α therapy has not been 
investigated in detail, but an increased risk in patients with rheumatoid arthritis was 
recently demonstrated. Epidemiological data on Japanese patients with rheumatoid 
arthritis revealed that the use of TNF-α inhibitors is a significant independent risk factor 
for serious infection when compared to treatment with nonbiological disease-modifying 
antirheumatic drugs (relative risk 2.37, 95% confidence interval (CI) 1.11–5.05, p = 0.026) 
[9]. Similarly, multivariate logistic regression analysis revealed that anti-TNF-α therapy 
was a significant risk factor for acute surgical site infection (odds ratio 5.69, 95% CI 2.07–
15.61, p = 0.0007) and that infliximab increased the risk of surgical site infection (odds 
ratio 9.80, 95% CI 2.41–39.82, p = 0.001) [10]. A shorter period after infliximab 
administration correlates with higher serum drug concentration, and thus we should be 
prudent in terms of surgery-associated intraocular infection in BD patients. 
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